^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    RD125

    i
    Other names: RD125, CT125A cells, fully human anti-CD5 chimeric antigen receptor T cells, CT125A CAR-T cells, RD-125, RD 125
    Associations

    News

    Trials
    Company:
    IASO BIO
    Drug class:
    CD5-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    6d
    Efficacy and safety of autologous CD5-KO anti-CD5 CAR-T cells in relapsed/refractory CD5+ hematological malignancies. (PubMed, Cell Rep Med)
    These findings demonstrate CT125A's therapeutic potential in CD5+ malignancies while highlighting the need for safety optimization. The trial has been registered at ClinicalTrials.gov (NCT04767308).
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • CD5 (CD5 Molecule)
    |
    RD125
    almost5years
    Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Huazhong University of Science and Technology
    Clinical • New P1 trial • CAR T-Cell Therapy
    |
    ALK (Anaplastic lymphoma kinase) • CD5 (CD5 Molecule)
    |
    ALK negative • CD5 positive
    |
    fludarabine IV • RD125 • cyclophosphamide intravenous